Incaier Files IPO Prospectus: Building an Ecological Anti-Cancer Network Through Innovative Full-Lifecycle Oncology Management

Cancer has become a major category of diseases that seriously threaten the life and health of Chinese residents, imposing a heavy burden on affected families.

According to data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, China recorded 4.57 million new cancer cases and 3 million cancer-related deaths in 2020, ranking first globally in both categories. Additionally, the total annual medical expenditure attributable to malignant tumors in China exceeds RMB 220 billion. Behind these figures lies the immense pressure borne by many families following a cancer diagnosis.

In the face of severe challenges, cancer prevention and control has become a concern for all partiesfocus of attention. Among these, early diagnosis and early treatment are particularly critical.Thus, at the policy level, the Outline of the “Healthy China 2030” Plan proposes to increase the overall five-year cancer survival rate by 15% by 2030 through early diagnosis and early treatment.

Against this backdrop, how are various industry stakeholders seeking solutions? What best practices have emerged? VCBeat will now provide a systematic analysis.

Cancer development is a process of cumulative exposure to risk factors across the entire lifespan.

Cancer prevention and control is not solely a concern for middle-aged and older adults; individuals of all ages should prioritize early cancer prevention, adopt healthy lifestyles, and avoid exposure to carcinogenic factors such as tobacco and alcohol, thereby reducing the risk of developing cancer.

Faced with more than 4 million new cancer cases each year, in addition to individual preventive measures, governments and industry associations are also actively exploring more solutions to reduce the incidence of cancer.

At the national level, China has established a prevention and control model for high-incidence cancer areas, built a tumor registration system and big data network covering 31 provinces and 574 tumor registries nationwide, as well as a nationwide early diagnosis and treatment network for cancer in urban and rural areas across all 31 provinces, along with a management system for cancer hospitals and a standardized quality control system for diagnosis and treatment.

As a professional association, the China Anti-Cancer Association has been hosting the National Cancer Prevention and Control Publicity Week annually, now in its 28th edition (April 15–21), to better educate the public on the fundamentals of cancer prevention and treatment.

However, this is far from sufficient; the prevention and treatment of tumors require stakeholders across the industry to provide more and better solutions.

First, on the treatment front, there is a continuous need for the introduction of new technologies and therapies. These include targeted drugs, innovative devices for tumor ablation, and immunotherapies. For instance, mRNA technology, which was successfully applied in COVID-19 vaccines, has recently achieved new breakthroughs in the treatment of solid tumors. Moreover, combination therapy has become a prevailing trend. The FDA has already approved several combination regimens for different types of cancer, and more clinical trials are underway to evaluate combinations of immunotherapy with radiotherapy, chemotherapy, targeted therapy, and other immunotherapeutic agents, aiming to enhance anti-cancer efficacy.

Second, in the realm of early diagnosis and treatment, niche segments represented by cancer early screening are beginning to rise, giving birth to star enterprises such as New Horizon Health, ClearMed Biotech, Geneseeq Technology, Genetron Health, and Burning Rock Biotech. Notably, with the rapid development of related technologies such as high-throughput gene sequencing, circulating tumor cell (CTC) detection, and gene methylation testing, cancer early screening has gradually overcome the dual pressures of technology and cost, possessing the internal conditions for accelerated development. Currently, the primary challenges lie in enhancing user awareness and market promotion.

Third, on the service provider side, a number of domestic oncology hospitals are continuously leveraging their core strengths to pursue differentiated development paths. For instance, Hygeia Healthcare’s core business involves operating oncology-focused hospitals and collaborating with third-party hospitals to manage radiotherapy centers. Fudan University Shanghai Cancer Center has jointly established a specialized disease-specific research data platform with Lianren Health to accelerate digital transformation, thereby enhancing treatment outcomes and service capabilities for cancer patients.

It is with the assistance of multiple stakeholders that China’s cancer prevention and control efforts are undergoing encouraging changes: to date, the overall five-year cancer survival rate has risen from 30.9% a decade ago to the current 40.5%.

Despite notable breakthroughs, it is essential to recognize with clarity that the prevention and treatment of tumors still face numerous challenges.

Behind this lies the pressure from the annually rising number of new cancer cases, as well as the urgent need to improve patients’ quality of life amid the trend toward managing cancer as a chronic disease. Therefore,Increasing technological innovation and the supply of medical resources across all stages—including prevention, diagnosis, treatment, and rehabilitation—has become a pressing issue that the industry must continually address.

As the World Health Organization points out, one-third of cancers are entirely preventable, one-third can be cured through early detection, and one-third can have their progression slowed, suffering alleviated, and quality of life improved by employing existing medical interventions.

Under this logic, the state vigorously promotes the concept of tertiary prevention of cancer.: Primary prevention refers to etiological prevention, secondary prevention focuses on early diagnosis, and tertiary prevention is implemented after the clinical detection of tumors. This approach will effectively reduce cancer incidence and mortality rates, while improving early diagnosis rates and survival rates.

So, what can the industry do around tertiary prevention? Ultimately, the core objective is to focus on the entire disease process, centering on patients for early prevention, early detection, early diagnosis, and early treatment.

In response to this,Haier’s health and wellness brand, INKON Life, has adopted an ecosystem-based strategy for cancer prevention., focusing on meeting patient needs and enhancing the healthcare experience, grounded in the full industrial ecosystem of oncology specialty. Through product and disciplinary innovations across stages including preventive screening, diagnostic testing, primary treatment, and rehabilitation management, we provide systematic, standardized, and innovative solutions for patients. By extensively integrating cutting-edge technologies and resources from related fields to foster ecological co-creation, we jointly deliver one-stop “prevention, diagnosis, treatment, and rehabilitation” services to patients.

How should this be understood? This requires an examination of the current pain points in cancer prevention and treatment, specifically identifying the issues recognized by INKON Life and its corresponding solutions. This can be analyzed from the following three major aspects.

First, from the patient’s perspective, the current challenge lies in implementing whole-chain cancer prevention and treatment—namely, how to broaden innovative solution pathways for patients across early prevention, diagnosis, treatment, and rehabilitation, while accelerating the research, development, and application of medical devices.

Sichuan Friendship Hospital, under INKON Life, is a Grade 3A hospital with strengths in oncology treatment and serves as the Cancer Prevention and Control Center of Jinjiang District, Chengdu. The hospital is currently exploring innovative models for full-lifecycle cancer management.

In detail, Sichuan Friendship Hospital centers on the goal of “early screening, early diagnosis, and early treatment” by innovating cancer prevention publicity, implementing cancer screening models, and strengthening capabilities in cancer diagnosis and treatment. The hospital provides patients with comprehensive prevention and control services spanning health education on cancer prevention, screening and assessment, early diagnosis and treatment, standardized clinical care, and follow-up management. For instance, it offers customized “1+X” early cancer screening packages, defined as “one routine health checkup item plus X specialized examinations for specific cancer types,” to conduct targeted early cancer screening.

Furthermore, Sichuan Friendship Hospital leverages Internet and Internet of Things (IoT) technologies to establish a 5G Diagnosis and Treatment Center and an integrated online-offline cloud platform for tumor treatment and rehabilitation experiences. This initiative breaks down the temporal and spatial barriers of medical resources, enabling real-time, zero-distance interaction between patients and specialists. Meanwhile, the hospital has also built a communication platform for complex and difficult tumor cases, providing technical training and guidance for professional cancer prevention and control teams across the region, thereby effectively enhancing the regional level of tumor treatment.

In terms of innovation in oncology treatment equipment, Masep, an IoT-based oncology treatment technology ecosystem brand under INKON Life, has been deeply engaged in the field of radiotherapy equipment for over 20 years. Through continuous iteration, it has become a representative enterprise in China with independent intellectual property rights for the research, development, and production of Gamma Knife systems, having cumulatively treated more than 100,000 patients. Currently, centering on tumor prevention, diagnosis, treatment, rehabilitation, and home health management, Masep has expanded its product R&D and manufacturing from oncology treatment equipment to tumor rehabilitation products, continuing to deepen its innovation in smart medical devices.

In addition to prioritizing technological R&D, Masep also places significant emphasis on the equitable accessibility of its technologies. This January, Masep donated the first Gamma Knife in the Tibet Autonomous Region to Nyingchi City, thereby better serving the health needs of the local population through a model that integrates medical equipment with healthcare resources.

Second, from the perspective of healthcare service supply, China currently faces imbalanced and inadequate development of medical resources, making it difficult for many cancer patients in lower-tier cities and towns to access medical care.

How can equitable access to healthcare services be promoted? INKON Life’s solution is to continuously build an integrated online-offline medical network spanning prevention, diagnosis, treatment, and rehabilitation.

For instance, it has established regional medical centers across China’s five major economic zones, linking high-quality oncology diagnosis and treatment resources for patient use. It currently operates nearly 20 hospitals, including Sichuan Friendship Hospital, Yuncheng First Hospital, Suzhou Guangci Oncology Hospital, Shanghai Yongci Rehabilitation Hospital, and Shanghai Yingkang Nursing Home.

INKON Life has also strengthened its multidisciplinary capabilities and extended them to hospitals across various regions, thereby enhancing specialty development, breaking down geographical barriers to medical resources, and facilitating the cross-regional flow of leading specialties and high-quality medical resources.

Sichuan Friendship Hospital’s Oncology Department has benefited from this approach. By adopting a patient-centric model and leveraging its internet hospital, IoT technologies, and the Digital Experience Cloud Platform, the department drives innovation in technology, products, services, and patient experience, while implementing multidisciplinary team (MDT) care to provide patients with a one-stop, full-scenario medical service experience.

Moreover, Sichuan Friendship Hospital has proactively extended its outreach to grassroots levels, providing robust technical support to primary healthcare institutions. It has established green channels for patients with critical, emergency, and severe oncological conditions, ensured medical service guarantees for these grassroots units, and created diverse opportunities for professional exchange among their staff. These initiatives have significantly enhanced the accessibility of top-tier medical resources.

Beyond replicating medical capabilities, achieving equitable healthcare access requires extending services to broader geographic areas and larger populations. Guided by this principle, Yuncheng First Hospital has actively promoted cancer prevention initiatives in rural areas, conducted free clinical consultations, and provided support in diagnostic monitoring, primary treatment, and supportive care, thereby enabling more villagers to undergo early screening and diagnosis.

Third, in building a cancer prevention and treatment system, the impact of any single entity is often limited; therefore, it is essential to engage more innovative partners to co-create an ecosystem.

In the course of oncology research, biobanks serve as a critical source for basic life science and clinical research, representing a core component in sample validation and the rapid translation of biomedical advances into clinical practice. In particular, the prospective nature and shareability of biobank data are of significant importance for effectively enhancing the application value of biospecimens in scientific research and clinical medicine; therefore, achieving high-quality storage is essential.

Haier Biomedical, under the Yingkang Yisheng umbrella, has innovatively developed a comprehensive IoT solution for biobanks. By integrating IoT technology, the solution establishes an intelligent “central brain” management system, featuring modules such as data dashboards, IoT monitoring, and data analytics. It enables high-quality, fully automated processing and preservation of samples, maximizing convenience in sample retrieval, enhancing security through digital management, and ensuring worry-free automated storage.

To date, Haier Biomedical has supported the establishment of tumor biobanks across China, including those at Yunnan Cancer Hospital, Hebei Center for Esophageal Cancer Prevention and Treatment, The Fourth Hospital of Hebei Province, Henan Cancer Hospital, and the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences.

It is evident that Haier Biomedical, together with universities, research institutions, and innovation centers, has established a technological innovation network for cancer prevention and treatment. This network facilitates the sharing and circulation of advanced technologies and best practices within the ecosystem, thereby providing more treatment options and hope to cancer patients through collaborative efforts.

As can be seen above, INKON Life adopts a patient-centric approach. Internally, it has established a comprehensive management framework covering the entire course and lifecycle of cancer care. Externally, through an open ecosystem and collaborative co-creation, it offers a holistic ecological strategy for cancer prevention. By leveraging technologies such as the Internet of Things (IoT), INKON Life breaks down the boundaries of medical services, enables interconnectivity among all industry stakeholders, and ultimately builds an integrated cancer prevention and control system spanning prevention, diagnosis, treatment, and rehabilitation, thereby truly serving human health.

In summary, centered on the three levels of prevention, stakeholders across the industry are actively exploring one-stop “prevention, diagnosis, treatment, and rehabilitation” services for patients, thereby promoting the equitable access to advanced technologies and high-quality medical resources and making healthcare services more compassionate.

Furthermore, leveraging its accumulated experience in product R&D and medical services, industries represented by INKON Life have not only built their own service capabilities but also empowered the broader industry with these capabilities, thereby driving overall sectoral advancement. This, in fact, offers a strategic direction for exploring “value-based healthcare.”

Currently, the incidence rate of cancer in China remains high, posing a significant challenge to tumor prevention and control.

However, we believe that with the continued exploration and efforts of all stakeholders in the industry, China’s prevention and control system will make even greater progress, benefiting a growing number of people.